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Abstract 
Chromatographic separation f highly polar basic drugs with 
ideal ionspray mass spectrometry volatile mobile phases is a 
difficult challenge. A new quantification procedure was developed 
using hydrophilic interaction chromatography-mass spectrometry 
with turbo-ionspray ionization in the positive mode. After 
addition of deuterated internal standards andsimple clean-up 
liquid extraction, the dried extracts were reconstituted in 500 pL 
pure acetonitrile and 5 pL was directly injected onto a Waters 
Atlantis TM HILIC 150- x 2.1-mm, 3-pm column. Chromatographic 
separations of cocaine, seven metabolites, and anhydroecgonine 
were obtained by linear gradient-elution with decreasing high 
concentrations of acetonitrile (80-56% in 18 min). This high 
proportion of organic solvent makes it easier to be coupled 
with MS. The eluent was buffered with 2mM ammonium acetate 
at pH 4.5. Except for m-hydroxy-benzoylecgonine, the within-day 
and between-day precisions at 20, 1 0, and 500 ng/mL were 
below 7 and 19.1%, respectively. Accuracy was also below 
_+ 13.5% at all tested concentrations. The limit of quantification 
was 5 ng/mL (%Diff < 16.1, %RSD < 4.3) and the limit of 
detection below 0.5 ng/mL. This method was successfully applied 
to a fatal overdose. In Switzerland, cocaine abuse ha  dramatically 
increased in the last few years. A 45-year-old man, a known 
HIV-positive drug user, was found dead at home. According to 
relatives, cocaine was self-injected about 10 times during the 
evening before death. A low amount of cocaine (0.45 mg) was 
detected in the bloody fluid taken from a syringe discovered near 
the corpse. Besides injection marks, no significant lesions were 
detected during the forensic autopsy. Toxicological investigations 
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showed high cocaine concentrations in all body fluids and tissues. 
The peripheral blood concentrations f cocaine, benzoylecgonine, 
and methylecgonine were 5.0, 10.4, and 4.1 rag/L, respectively. 
The brain concentrations of cocaine, benzoylecgonine, and 
methylecgonine were 21.2, 3.8, and 3.3 mg/kg, respectively. 
The highest concentrations of norcocaine (about 1 mg/L) were 
measured in bile and urine. Very high levels of cocaine were 
determined in hair (160 ng/mg), indicating chronic cocaine use. 
A low concentration of anhydroecgonine methylester was also 
found in urine (0.65 rag/L) suggesting recent cocaine inhalation. 
Therapeutic blood concentrations of fluoxetine (0.15 rag/L) and 
buprenorphine (0.1 pg/L) were also discovered. A relatively high 
concentration of Ag-THC was measured both in peripheral blood 
(8.2 pg/L) and brain cortex (13.5 pg/kg), suggesting that the victim 
was under the influence of cannabis at he time of death. 
In addition, fluoxetine might have enhanced the toxic effects of 
cocaine because of its weak pro-arrhythmogenic properties. 
Likewise, combination of cannabinoids and cocaine might have 
increase detrimental cardiovascular effects. Altogether, these
results indicate a lethal cocaine overdose witha minor contribution 
of fluoxetine and cannabinoids. 
Introduction 
According to the Swiss Federal Office of Public Health, 10% 
of the population between 15 and 39 had used illicit drugs at 
least once in 1997. Although most of these cases involved 
cannabis, about 30,000 people had a prevalence for cocaine 
[http://www.bag.admin.ch/e/]. In the same y ar, 7% of men be- 
tween 25 and 39 admitted taking cocaine at least once during 
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their lifetimes, up from 3.9% in 1992. Furthermore, there were 
approximately 250 drug-related deaths, with an additional 150 
drug users dying of AIDS (1). Forensic investigations carried 
out at our institute show similar patterns in the French part of 
Switzerland. There was a threefold increase in the number of 
cocaine-related deaths in the last three y ars. These statistics 
are concordant with a price drop and an increase in accessi- 
bility, showing that cocaine has been becoming a popular recre- 
ational drug among teenagers and young adults. The route  of 
administration have also changed with more opiate addicts 
under methadone substitution therapy injecting or inhaling co- 
caine (2-5). The acute effects of cocaine are an intense eu- 
phoria, a heightened energy level, enhanced alertness, and self 
confidence. This euphoric phase is followed by depression and 
craving for the drug (6,7). Cocaine has two well-defined phar- 
macological effects: it is a local anesthetic and a monoamine 
blocker that interferes with catecholaminergic and seroton- 
ergic neurons. Serotonin is believed to be important in the 
euphoric effects of cocaine because administration of flu xetine, 
a serotonin reuptake blocker, attenuates the positive reinforcing 
action of cocaine in rats (8). At high concentrations, cocaine 
also acts on cholinergic receptors, contributing to he hemo- 
dynamic responses and cardiovascular toxicity (9). Vasospasm 
and thrombus formation, rupture of ce bral neurysms and in- 
tracranial hemorrhage, cardiac ischemia, stroke, seizures, and 
sudden death are the consequences of this toxicity (7,10,11). In- 
travenous intake or inhalation of cocaine results in a rapid 
onset because of fast increases in plasma levels often exceeding 
1-2 mg/L (12). Symptoms of toxicity generally occur with some 
delay after peak concentrations of cocaine in the blood. How- 
ever, the peak plasma values vary considerably between indi- 
viduals. In addition, only poor dose-response relationship to 
toxicity exists, complicating the interpretation of blood levels 
(6). The elimination half-life of cocaine in plasma is in the 
range of 40 to 90 rain in humans (13,14). While a small pro- 
portion of cocaine is excreted unchanged into urine, the 
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Figure 1. Metabolic pathways and pyrolysis of cocaine. 
majority is hydrolyzed by plasma nd liver carboxylesterases, 
yielding benzoylecgonine (BE) and ecgonine methylester 
(EME). Spontaneous chemical hydrolysis of cocaine into ben- 
zoylecgonine may also occur (15,16). Pyrolysis of cocaine 
during smoking results in the formation of methylecgonidine 
or anhydroecgonine methylester (AEME) (17). Figure 1 de- 
picts the main cocaine pyrolysis and metabolic pathways. Liver 
P 450 enzymes N-demethylate a small a ount of cocaine to 
produce norcocaine (NCOC) which is hepatotoxic (18). If 
ocaine is used in conjunction with ethanol, a transesterifica- 
tion reaction occurs forming cocaethylene or ethylcocaine (CE) 
(19,20). CE is further metabolized into ecgonine ethylester 
(EEE) and BE. Aromatic hydroxylation of cocaine may also 
occur resulting in the formation of meta- (m-OH-COC) and 
para- substituted hydroxy-cocaine and hydroxy-benzoylecgo- 
nine (m-OH-BE). The latter has been shown to be present 
in significant concentrations in the meconium of cocaine- 
exposed babies (21). 
Gas chromatography-mass spectrometry (GC-MS) operating 
in the SIM mode is the method most frequently used for the 
analysis of cocaine and metabolites in biological samples (6). To
achieve acceptable sensitivity, metabolites of cocaine must be 
derivatized prior to analysis. An alternative method to GC-MS 
is liquid chromatography-mass spectrometry (LC-MS) with 
the advantages of no required derivatization step and negligible 
thermal degradatiofl during injection and artifactual forma- 
tion of AEME (22). The method has been successfully applied to 
urine samples after solid-phase extraction (23). Chromatog- 
raphy is generally carried out on ODS reversed-phase columns 
interfaced with either ES or APCI sources (24). Flow-injection 
ionspray-MS-MS is also possible (25). 
We present a new quantification procedure using hydrophilic- 
interaction chromatography-mass spectrometry (HILIC-MS) 
with turbo ionspray ionization in the positive mode. A silica- 
packed Atlantis HILIC column (Waters, Rupperswil, Switzer- 
land) is well suited for LC-MS analysis because separation of 
cocaine and its metabolites is obtained with high concentra- 
tions of acetonitrile (26,27). The method was successfully ap- 
plied to a death case after multiple cocaine injections. The 
cocaine and metabolite distribution was determined inseveral 
biological fluids and tissues. 
Methods for Cocaine Analysis 
Materials and solvents 
Cocaine standards, metabolites as well as their deuterated ho- 
mologues were purchased from Lipomed (Lipomed AG, 
Arlesheim, Switzerland) and CIL (Cambridge Isotope Labora- 
tories, Innerberg, Switzerland). A 100 pg/10 mL stock solution 
of deuterated compounds [cocaine-(N-methyl-d3), benzoylec- 
gonine-(N-methyl-d3), ecgonine methylester-(N-methyi-d3), 
anhydroecgonine m thylester-(N-methyl-d3), and norcocaine- 
(d3-methylester)] in acetonitrile was prepared and stored at 
-20~ Four working solutions were prepared in acetonitrile. 
The first two contained cocaine, benzoylecgonine, ecgonine 
methylester, and cocaethylene in 10 and 1 IJg/mL, and the 
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two others contained anhydroecgonine m thylester, m-hy- 
droxybenzoylecgonine, orcocaine, norcocaethylene, and ec- 
gonine ethylester in the same concentrations. All standard 
solutions were prepared and used with glass Hamilton syringes 
(Hamilton, Bonaduz, Switzerland). Acetonitrile (HPLC grade, 
quality gradient) was obtained from Riedel-de HaEn (Fluka, 
Buchs, Switzerland). Ammonium acetate and acetic acid (Bio- 
chemika grade), potassium chloride, chloroform, and iso- 
propanol (puriss grade) were purchased from Fluka. Boric acid 
and potassium carbonate were purchased from VWR Merck 
Eurolab (Dietikon, Switzerland). Deionized water was purified 
by a Milli-Q system (Millipore). The borate buffer was prepared 
by mixing 700 mL of a solution containing 61.8 g boric acid and 
74.6 g potassium chloride in 1 L of distilled water and 300 mL 
of another solution containing 106 g potassium carbonate to 
reach a pH of 8.4. The borate buffer and the extraction solution 
of chloroform/isopropanol (3:1, v/v) were stored at room tem- 
perature. 
Biological specimens 
The blank blood samples were obtained from the local hos- 
pital blood bank. Biological fluids an  tissues pecimens from 
the victim were taken during the autopsy. Blood samples were 
collected in 5.5 mL S-Monovettes containing 1 mg fluoride/mL ' 
and 1.2 mg EDTA/mL blood as preservatives (Sarstedt, Sevelen, 
Switzerland). Tissues w re manually homogenized with a Teflon 
pestle and a Potter-Elvehjem glass homogenizer in 5 mL 0.9% 
saline. 
Instrumentation 
The LC-MS system consisted of two high-pressure Perkin 
Elmer series 200 micro pumps, a series 200 autosampler, and 
a Lee-Visco-Jet micro-Mixer with 10 tJL internal volume con- 
nected to an Applied Biosystems MDS Sciex API 150EX single- 
quadrupole system (Applera Europe, Rotkreuz, Switzerland). 
For atmospheric pressure ionization, a turbo-ionspray interface 
was used. The modules were controlled by a Macintosh com- 
puter unning OS 8.1, and data collection was performed using 
MassChrom 1.4 software. Quantitative results were processed 
with TurboQuan 1.0 software. The calibration curves were ob- 
tained by weighted (l/x) least-squares linear through zero or 
quadratic regression analysis. 
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Extraction procedure 
The internal standards (10I~g/mL acetonitrile) and aliquots 
of both working solutions of standards for the calibration curve 
(10 or 1 IJg/mL acetonitrile) were added to 10 mL Pyrex SVL 
tubes (GlasKeller, Basel, Switzerland) nd evaporated under 
N2 at 37~ Then 1 mL blank blood, biological fluid, or tissue 
homogenate; 2 mL borate buffer (pH 8.4); and 3 mL of chloro- 
form/isopropanol (3:1, v/v) (added with a digital dispenser Cal- 
ibrex 520, Socorex, ReactoLab, Servion, Switzerland) were 
vortex mixed for 1 min and extracted for 30 min on a horizontal 
shaker at 180 motions/min (Edmund B~ihler, GlasKeller, Basel). 
After centrifugation (30 min, 3000 rpm), the lower organic 
phase was collected and evaporated under N2, and the dried ex- 
tract was reconstituted into 500 IJL of acetonitrile prior to 
LC-MS analysis. Biological samples wereappropriately diluted 
(generally 2 or 10 times) in order to yield results inside the 
quantification range. 
Chromatography 
A Waters Atlantis HILIC silica column (150 x 2.l-ram i.d., 3- 
IJm particle size) and guard columns (10 x 2.1 ram, 3 IJm) 
packed with the same material were purchased from Waters. 
Cocaine derivatives w re separated atroom temperature (23~ 
by gradient elution of an acetonitrile/2mM ammonium acetate 
buffer eluent at a flow-rate of 250 IJL/min. The pH of the eluent 
was adjusted to 4.5 with acetic acid. Before injection, the 
column was prewashed for 10 rain with the starting eluent. 
After a 5-1JL injection, an isocratic elution was performed with 
80% acetonitrile for 1 rain. From then on, a gradient elution of 
acetonitrile decreased linearly to 56% in 18 rain. This latter 
concentration was maintained for 1 rain. Subsequently, the 
system was returned to its initial conditions in 
1 rain and equilibrated for 10 rain before injection of the next 
sample. 
MS conditions 
The MS was operated in the positive mode. Nitrogen was 
used as a nebulizing, heating, and curtain gas. The gas flow 
rates were set to about 0.9 L/rain (nebulizer gas setting = 9), 
7 L/rain, and 0.9 L/rain (curtain gas setting = 9) respectively. 
The Turbo probe temperature was 475~ and the Ionspray 
voltage was set at 3600 V. The voltages of the orifice and of the 
Table I. LC-MS Parameters for Cocaine, Cocaine Metabolites, and Anhydroecgonine Methylester 
Retention Time 
Retention (%RSD, Selected Internal JS Selected Fit 1/x LOD 
Analyte Time (min) n = 12) Jon (m/z) Standard (IS) Ion (m/z) Weighted (ng/mL) 
Cocaine 10.21 0.84 304.1 Cocaine-d~ 185.2 linear through 0 0.1 
Benzoylecgonine 5.49 1.89 290.3 8enzoylecgonine-d 3 293.22 linear through 0 0.3 
Ecgonine methylester 16.87 0.44 200.2 Ecgonine methylester-d3 203.2 linear through 0 0.5 
Cocaethylene 9.89 0.78 318.2 Cocaine-d3 185.2 linear through 0 0.1 
m-Hydroxybenzoylecgonine 4.68 1.21 306.1 Benzoylecgonine-d~ 293.22 quadratic 1.5 
Ecgonine ethylester 15.22 0.48 214.1 Ecgonine methylester-d~ 203.2 quadratic 0.3 
Anhydroecgonine methylester 13.82 0.64 182.1 Anhydroecgonine methylester-d~ 185.2  quadratic 0.2 
Norcocaine 9.32 0.90 290.1 Norcocaine-d~ 293.22 quadratic 0.3 
Norcocaethylene 9.10 0.94 304.1 Norcocaine-d3 293.22 quadratic 0.1 
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focusing ring were optimized byflow injection at a flow-rate of 
250 I~L/min and found to be similar for all cocaine d rivatives, 
that is, 10 and 130 V for the orifice and ring, respectively. The 
composition of the eluent was 70% acetonitrile and 30~ am- 
monium acetate buffer. Twelve ions corresponding to he pro- 
tonated molecules or i n fragments, monitored in the SIM 
mode for quantification are listed in Table I along with the re- 
tention time of the corresponding substance. The dwell-time 
was set at 200 ms. Calibration of the mass analyzer was per- 
formed by infusion of a PPG (polypropylene glycol) standard 
mixture using a Harvard syringe pump at a flow-rate of 0.6 
mL/h. 
Validation 
The validation procedure was adapted from (28). The evalua- 
tion of linearity was carried out with blood. Blank matrix was 
spiked with the internal standards mix (500 ng/mL) and with 
cocaine derivatives at nine different levels, yielding calibration 
points at 2, 5, 10, 20, 50, 100, 200, 500, and 1000 ng/mL. The re- 
coveries were determined by spiking a blood-blank matrix with 
500 ng/mL before and after sample preparation (n = 5). Matrix 
suppression was studied by extracting a blank matrix and 
spiking the extract with both cocaine derivatives and thein- 
ternal standards at concentrations of 20, 100, and 500 ng/mL 
into the organic layer (n = 5) (29). These samples were com- 
pared to reference samples that were prepared by spiking the 
same substances into the organic layer. The ion suppression ef- 
fect was then assessed by calculating the area ratio between the 
peak areas obtained in the presence and in the absence of co-ex- 
tracted potential interferences. In order to determine the limit 
of detection (LOD: signal-to-noise ratio > 3), samples con- 
taining low concentrations of cocaine derivatives (down to 0.1 
ng/mL) were prepared and analyzed between two blank probes. 
The limit of quantification was set at 5 ng/mL, accuracy and pre- 
cision values (< 120%1) were checked by carrying out five de- 
terminations. The selectivity of the method was studied by 
including one blank sample containing no internal standard and 
one specimen spiked with the deutarated internal standards 
mix only in each batch. Furthermore, quality control samples 
(Medidrug BTMF 1/03-A S-plus or BTMF 2/01-A S-plus) known 
to contain cocaine, cgonine methylester, and benzoylecgo- 
nine were monitored and checked for the absence of other 
derivatives and acceptable quantitative levels. 
Because of the high temperature of the turbo-ionspray 
(475~ the conversion of cocaine into AEME during LC-MS 
analysis was assessed by injecting hi h concentrations of co- 
caine (500 and 100 ng/mL) and measuring AEME concentration 
down to 0.1 ng/mL. 
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Figure 2. Total ion (TIC) and extracted ion (XlC) chromatograms of an extract of blood spiked with 50 ng/mL of cocaine derivatives. Left: m-BE-OH = meta- 
hydroxy-benzoylecgonine, NCE = norcocaethylene, COC = cocaine, AEME = anhydroecgonine methylester; right: BE = benzoylecgonine, NCOC = nor- 
cocaine, CE = cocaethylene, EEE = ecgonine ethylester, and EME = ecgonine methylester. 
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Additional Methods for Case Report Investigations 
Screening methods 
A comprehensive drug screening was carried out according to 
known procedures (30). Urine was screened by immunoassays 
and GC-MS methods. Basic extracts as well as hydrolyzed and 
acetylated basic extracts were analyzed. Volatile compounds 
were screened by headspace GC-flame-ionization detection 
(FID). Blood analysis was performed by high-performance liquid 
chromatography-diode-array detection (HPLC-DAD), and 
GC-MS. 
Hair analysis 
The method escribed by Girod and Staub (31) was used with 
some modifications: the whole hair sample (6 cm-long) was 
washed twice with 10 mL dichloromethane, dried in a folded 
filter paper, and cut in pieces of 1-3 ram. Twenty milligrams of 
hair fragments was added toI mL of methanol, 1 mL of phos- 
phate buffer (0.IM, pH 6.0), and 50 laL ofa deuterated standard 
solution (1 IJg/mL). After overnight incubation at 50~ the 
methanol/buffer extraction solution was diluted with 5 mL of 
phosphate buffer (pH 6.0). It was then transferred to a precon- 
ditioned mixed-phase extraction column (ChromaBond Drug, 
200 rag, 3 mL) (Macherey-Nagel, Oensingen, Switzerland). The 
column was washed with 2 mL 1.0M acetic acid and 3 mL 
methanol. After 5 rain air-drying, thedrugs were eluted with 3 
mL of a dichloromethane/2-propanol/ammonium hydroxide 
(80:20:2, v/v/v) mixture. After evaporation under N2, the dried 
residues were derivatized for 30 min at 80~ with trifluoroacetic 
anhydride, hexafluoro-2-propanol and ethyl acetate. One mi- 
croliter was injected into the GC-MS system operating in the 
SIM mode. The following ions were monitored: m/z 182, 272, 
303 (cocaine); rn/z 318, 334, 439 (benzoylecgonine); and m/z 
182,264,295 (ecgonine methyl ester), and the ions for the d3 
homologues were rn/z 185, 275, 306; rn/z 321,337,442; and r /z 
185, 267, 298, respectively. 
Buprenorphine analysis 
Buprenorphine and norbuprenorphine  peripheral blood 
and urine were determined by turbo-ionspray LC-MS oper- 
ating in the positive mode according to a procedure adapted 
from Tracqui et al. (32). Buprenorphine-d4 and norbuprenor- 
phine-d3 (CIL, Innerberg, Switzerland) were used as internal 
standards at a concentration f 10 and 20 ng/mL, respectively. 
Urine was hydrolyzed with E. coli [3-glucuronidase prior to pu- 
rification through three successive base-acid-base extraction 
steps. A calibration curve was obtained with 7 standard con- 
centrations between 0.1 and 10.0 ng/mL. The dried extracts 
were reconstituted in 100 laL of the mobile phase made of 20% 
acetonitrile and 80% ammonium formate (lmM, pH 3.8). HPLC 
separations were performed on a Waters XTerra MS C8 3.5- 
jam, 150- x 2.1-mm column fitted with a XTerra MS C8 10- x 
2.1-mm precolumn. Isocratic elution at a flow rate of 250 
laL/min was kept for the first 5 min following a 10-1aL 
injection. The acetonitrile wasthen increased up to 80% in 
2 steps: from 20 to 60% in 10 min and then from 60 to 80% in 
5 rain. The following ions were monitored: m/z 468.3 
(buprenorphine), 472.22 (buprenorphine-d4), 414.25 (nor- 
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buprenorphine), and 417.25 (norbuprenorphine-d3). T e neb- 
ulizer, curtain gas, and ionspray voltage were set at 12, 10, and 
3500 V, respectively. The turbo-ionspray temperature was 
480~ The orifice and ring voltages for buprenorphine w re of 
66 and 260 V; those for norbuprenorphine were 56 and 230 V, 
respectively. Ten microliters was then injected onto the column. 
Fluoxetine analysis 
Fluoxetine and norfluoxetine were analyzed according to a
procedure adapted from Crifasi et al. (33). Blank blood samples 
were fortified with fluoxetine and norfluoxetine (Sigma-RBI) at 
a concentration of 0, 0.05, 0.1, 0.2, 0.5, 1.0, and 5.0 I~g/mL. After 
addition of the internal standard paroxetine (5.0 IJg/mL) and of 
a saturated ammonium buffer (pH 9.5), the antidepressants 
were extracted into a chloroform/isopropanol (9:1, v/v) solution. 
After solvent evaporation under N2, they were acetylated an  an- 
alyzed by GC-MS operating in the SIM mode. The following 
ions were monitored for acetylated fluoxetine and acetylated 
norfluoxetine, respectively: m/z 86, 117, 190 and m/z 72, 117, 
176. 
Cannabinoids analysis 
The method of quantification of A9-tetrahydrocannabinol 
(THC), 11-hydroxy-Ag-tetrahydrocannabinol (11-OH-THC) and 
ll-nor-A9-tetrahydrocannabinol carboxylic acid (THCCOOH) 
in blood by GC-MS after solid-phase extraction has been de- 
scribed elsewhere (34). Total THCCOOH was determined by 
GC-MS in urine after basic hydrolysis, extraction on SPEC 
column (Ansys purchased from Varian, Stehelin AG)and silyl- 
ation with MSTFA (Macherey-Nagel, Oensingen, Switzerland) 
according to a procedure adapted from Wu et al. (35). THC- 
COOH-d~ (CIL, Innerberg, Switzerland) was used as internal 
standard. 
Case history 
A 45-year-old man, a known HIV-positive drug user. was found 
dead at home. According to relatives, the previous day, he in- 
jected himself with 10 cocaine doses. Cardiopulmonary reani- 
mation was attempted without success. Several syringes were 
found nearby, one containing about half a milliliter of a bloody 
fluid. No evidence of violence wasfound. Forensic autopsy was 
carried out the following day. Biological specimens were taken 
for toxicological investigations. 
Results and Discussion 
Validation of HI/IC-MS procedure 
for cocaine determination 
A chromatographic profile  total (TIC) and extracted (XIC) 
cocaine ions, its main metabolites, and anhydroecgonine 
methylester ata concentration f 50 ng/mL of blood are shown 
in Figure 2. All XIC peaks are symmetric and well resolved. 
Very clean XIC chromatograms were obtained without inter- 
fering molecules. The elution times and their variation (%RSD) 
are indicated in Table I. Only cocaine, CE, and their N-demethyl- 
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ated metabolites luted as a single cluster of partially overlap- 
ping peaks which could be resolved when specific ions were 
monitored (Figure 2). Matrix ion suppression was found to be 
less than 15% (n - 5) for all molecules at the three tested con- 
centrations (20, 100, and 500 ng/mL blood). Thermoconversion 
of cocaine into AEME during the LC-MS analysis did not occur 
because no trace of AEME could be detected own to a con- 
centration of0.1 ng/mL. The extraction scheme corresponds to 
a procedure which has been used for routine analysis of cocaine 
and metabolites by GC-MS in our laboratory for many years. 
The extraction yields were assessed at500 ng/mL. They were ex- 
cellent for cocaine and cocaethylene (83%); satisfactory for 
norcocaine, norcocaethylene, and benzoylecgonine (about 
50%); and poor for the other molecules (< 15%). The limit of 
detection (LOD) was estimated by injecting decreasing con- 
centrations ofcocaine and derivatives down to a signal-to-noise 
Table II. Accuracy (% Error) and Within-Day and Between-Day Precision 
(% RSD) at Three Concentrations (20, 100, and 500 ng/mL) and Accuracy 
and Within-Day Precision at LOQ (5 ng/mL) 
Concentration Accuracy WD Precision BD Precision 
Drug (ng/mt) (• Diff, n = 5) (%RSD, n = 5) (%RSD, n = 25) 
Cocaine 5 0.6 3.7 - 
20 -9.7 1.6 10.4 
100 -1.4 1.9 7.3 
500 -2.4 2.6 7.4 
Benzoylecgonine 5 13.8 1.2 - 
20 5.9 1.7 14.5 
100 1.1 1.4 3.8 
500 2.8 2.3 2.5 
Ecgonine methylester 5 7.9 4.3 - 
20 0.5 3.2 3.4 
100 0.3 1.1 3.6 
500 2.5 0.6 2.9 
Cocaethylene 5 16.1 3.4 - 
20 13.5 2.7 18.2 
100 -0.8 7.0 18.8 
500 -12,9 3.5 15.0 
m-Hydroxybenzoylecgonine 5 -14.6 25.5 - 
20 -7.3 15.3 12.0 
100 1.5 9.0 15.2 
500 -5.4 4.9 12.2 
Ecgonine ethylester 5 6.5 1.0 - 
20 7.2 3,1 7.3 
100 7.1 6.7 8.0 
500 -2.1 1.1 3.9 
Anhydroecgonine methylester 5 -2.2 2.9 - 
20 -2.4 2.0 12.1 
100 6.8 2.6 3.5 
500 2.3 2.4 3.4 
Norcocaine 5 0.4 2.4 - 
20 0.0 1.1 3.5 
100 4.4 2.4 2.0 
500 3.3 1.5 3.8 
Norcocaethylene 5 8.2 2.8 - 
20 9.0 2.2 19.1 
100 -2.3 2.8 7.4 
500 1.6 2.1 4.3 
ratio of 3. Except for m-hydroxybenzoylecgonine (LOD = 1.5 
ng/mL), the LODs of all cocaine derivates were between 0.1 
and 0.5 ng/mL of blood, indicating a good sensitivity despite a
poor extraction yield (Table I).With the exception of m-BE-OH, 
a very good limit of quantitation (LOQ) of 5 ng/mL was achieved 
for all molecules with an accuracy and %RSD precision lower 
than 16.1. As shown in Table I, an acceptable curve fitting in the 
2-1000 ng/mL range for COC, BE, EME, NCOC, and AEME 
was achieved with a 1/x weighted linear th ough zero regression 
(/9 > 0.998). The other cocaine derivatives for which no corre- 
sponding deuterated internal st ndard were used were better 
fitted with 1/x weighted quadratic regression (R > 0.997). 
Method accuracy ranged between -14.6% to +16.1% of the 
target value. The within day (WD) and between-day precisions 
(BD) were determined at20, 100, and 500 ng/mL of blood (n = 
5) and found to be satisfactory and less than 15.3 and 19.1%, re- 
spectively. The main statistical parameters of
the validation procedure are listed in Table II. 
For the limit of quantification (LOQ), the 
second lowest point of the calibration curve 
(i.e., 5 ng/mL) was adopted. At this concentra- 
tion, the accuracy expressed as the percentage 
difference to the target value was less than 
• 16.1 for all cocaine derivatives. The precision 
remained lower than RSD% = 4.3, with the ex- 
ception of m-OH-BE which was 25.5 for 5 mea- 
surements. 
In contrast to reversed-phase analysis, for 
which a very high proportion of water is often 
required to get enough retention f polar 
metabolites (e.g., EME), HILIC of a broad 
family of xenobiotic derivatives with a broad 
range of polarity indexes can be carried out 
with a relatively low amount of the water 
eluent. The advantages ofAtlantis HILIC silica 
are several: organic eluents immiscible with 
water (e.g., hexane) are not needed, acetonitrile 
constitutes a weak solvent and can be injected 
directly onto the column. Furthermore, mobile 
phases containing highly organic solutions (in 
this case acetonitrile) lead to favorable spraying 
conditions at the LC-MS interface necessary 
for adequate s nsitivity (26,27,36). 
Case results 
Paraphernalia 
The analysis of the bloody fluid found in the 
syringe by LC-MS revealed the presence ofco- 
caine at a concentration f 906 mg/L corre- 
sponding to a total amount of about 0.45 mg 
cocaine in 0.5 mL (Table III). 
Forensic autopsy 
Multiple old and recent injection traces were 
discovered. The deceased weighed 57 kg and 
was 171 cm tall. The heart weight was 330 g. 
Its macroscopic examination revealed a dis- 
crete arteriosclerosis of the coronary arteries 
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only. The other organs were macroscopically normal. 
The histological examination detected a smallfibrous patch 
in the lateral wall ofthe left ventricle. The microscopic exami- 
nation of the other organs showed a discrete thickening of the 
small renal arteries associated with a chronic inflammatory in- 
filtration. No lesions could be detected in the brain and in the 
liver. The presence ofmultiple injection wounds, the detection 
of a relatively high cocaine concentration in the syri ge dis- 
covered near the corpse, and the story of the relatives confirms 
the injection route. Drug addicts under substitution therapy are 
known to inject cocaine up to 30-40 times per day. This com- 
pulsive use of cocaine has grown to reach epidemic proportion 
in Switzerland, challenging drug rehabilitation treatment cen- 
ters. 
Toxicological results 
Screening results. A comprehensive drug screening of blood 
and urine was carried out by immunoassays, headspace 
GC-FID, HPLC-DAD, and GC-MS. Immunoassays were positive 
for cocaine, cannabinoids, and buprenorphine. Neither ethanol 
nor other volatile compounds could be detected in whole blood 
by headspace GC-FID. The c romatographic analyses per- 
formed by GC-MS operating in the scan mode and by 
Table III. Concentrations and Total Amounts of Cocaine 
and Cocaine Metabolites or Cocaine degradation 
Products Determined by HILIC LC-MS 
Ecgonine 
Syringe Cocaine Benzoylecgonine Methylester 
Total amount (rag) 0.45 0.12 0.04 
Concentration (mg/L) 906 230 81 
Table IV. Qualitative Results of Toxicological 
Investigations Obtained by Chromatographic Methods 
Specimen Xenobiotics 
Blood Cocaine Fluoxetine 
Benzoylecgonine Norfluoxetine 
Methylecgonine THC 
Anhydroecgonine methylester 11 OH-THC 
Norcocaine THCCOOH 
Hydroxy-benzoylecgonine Acetaminophen 
Buprenorphine Phenacetin 
Norbuprenorphine Cotinine 
Caffeine 
Urine Fluoxetine 
Norfluoxetine 
THCCOOH 
Acetaminophen 
Phenacetin 
Trimethoprim 
Lidocaine metabolites 
Cotinine 
Theobromine 
Caffeine 
Cocaine 
Benzoylecgonine 
Methylecgonine 
Anhydroecgonine methylester 
Norcocaine 
Hydroxy-benzoylecgonine 
Cinnamoylcocaine 
Buprenorphine 
Norbuprenorphine 
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HPLC-DAD and LC-MS revealed the presence of a large array 
of xenobiotics which are listed in Table IV. A few compounds 
(cannabinoids, buprenorphine, and m-OH-BE) which could be 
detected by dedicated quantitative methods only are also in- 
cluded in this table. Cocaine a dits two main metabolites and 
degradation products, benzoylecgonine and ecgonine 
methylester (15,16), were detected in all biological specimens 
submitted to toxicological investigations (Table V). Other 
metabolites, AEME, m-OH-BE, and NCOC were also detected 
(Table VI). 
Cocaine. When cocaine is smoked in a glass pipe as a free 
base, it is thermally degraded to benzoic acid, AEME and other 
degradation products (17). In the present case, according to rel- 
atives, cocaine was administered by injection. This routeof ad- 
ministration means that no AEME should be found. 
Nevertheless, AEME was detected! Several hypotheses can be 
formed to explain its presence. First, it could result from pre- 
vious cocaine inhalation because free-base smoking s also 
common among drug addicts. We can also assume that AEME 
was the consequence of thermal degradation of cocaine during 
volatilization i the injection port of the GC (37). In this second 
case, AEME should be considered as an artifactual contami- 
nant. This hypothesis could be ruled out because AEME was also 
detected by LC-MS. Finally, AEME could already bepresent in 
the powder as a manufacturing byproduct. AEME aswell as 
norcocaine and hydroxy-cocaine have been indeed detected in 
refined illicit cocaine (38). Because no cocaine sample was 
found near the body, this latter hypothesis could not be tested. 
The analysis of the syringe revealed the presence of a low 
amount of AEME that could originate from the powder or from 
the blood. The presence ofAEME must herefore be interpreted 
with caution. I  our opinion, inhalation of free-base cocaine fol- 
lowed by several injections is the most likely scenario. 
Norcocaine has been found in all screened biological speci- 
mens. NCOC is aN-desmethyl cocaine metabolite produced by 
liver cytochrome P-450 with hepatotoxic properties (18,39). 
Reports of hepatotoxicity attributed to cocaine use are rare (6) 
because NCOC is a minor metabolite (Table VI). In the present 
Table V. Body Fluid and Tissue Distribution of Cocaine, 
Benzoylecgonine, and Ecgonine Methylester Determined 
by HILIC-MS 
Ecgonine 
Specimen Cocaine Benzoylecgonine Methylester 
Peripheral blood 5.0 mg/L 10.4 mg/L 4.1 mg/L 
Cardiac blood 9.0 mg/L 20.1 mg/L 14.4 mg/L 
Pericardic liquid 9.9 mg/L 12.0 mg/L 8.4 mg/L 
CSF 4.1 mg/L 4.5 mg/L 2.6 mg/L 
Vitreous humor 5.3 mg/L 5.6 mg/L 2.6 mg/L 
Urine 47.9 mg/L 929.8 mg/L 283.3 mg/L 
Bile 5.3 mg/L 19.1 mg/L 6.2 mg/L 
Gastric contents 209.4 mg/kg 16.7 mg/kg 28.3 mg/kg 
Hair 160 ng/mg 37 ng/mg 19 ng/mg 
Brain cortex 21.2 mg/kg 3.8 mg/kg 3.3 mg/kg 
Skeletal muscle 9,6 mg/kg 7.1 mg/kg 3.7 mg/kg 
Liver 8.5 mg/kg 86.4 mg/kg 49.3 mg/kg 
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case, no significant hepatic lesions could be detected during au- 
topsy or by histology suggesting a minor involvement ofNCOC 
in the death. NCOC was also found in the brain (0.76 mg/kg) 
where it could contribute to oxidative stress, promoting neu- 
ronal toxicity (40). Liver esterases transform cocaine and al- 
cohol into cocaethylene which is further metabolized into 
ecgonine ethylester (19,20). None of these metabolites could be 
detected in significant amounts demonstrating that alcohol 
and cocaine were not taken simultaneously. 
According to Isenschmid (6), the most common clinical man- 
ifestations following acute cocaine intoxication include pro- 
found CNS stimulation with psychosis and repeated grand-real 
convulsions, ventricular rrhythmias nd respiratory dysfunc- 
tion with Cheyne-Stoke breathing and ultimately respiratory 
paralysis. Excited delirium accounts for another 10% of co- 
caine related deaths. 
An average blood level of 3.0 mg/L was observed for intra- 
venous fatalities (41), a concentration which is slightly lower 
than the peripheral blood level which was measured in our 
case (5.0 mg/L). Intravenous administration of 200 mg of co- 
caine in humans result in a similar mean plasma concentration 
of 3.2 mg/L (range: 2.53-3.87 rag/L) (13). Therefore, the bl od 
levels which are measured in living and dead people overlap to 
some extent. Moreover, the interpretation f cocaine blood 
levels is much more complicated because it is prone to chem- 
ical and enzymatic degradation (15) and to postmortem redis- 
tribution (42,43). To minimize drug degradation, biological 
specimens were collected rapidly and stored at -20~ until 
analysis. In addition, blood was preserved with fluoride and 
EDTA. Postmortem redistribution is exemplified bythe cardiac 
to peripheral blood concentration ratio of 1.8 (see Table V). A 
similar value has been fou d by others (44). Pericardial fluid co- 
caine concentration was similar to cardiac blood levels, whereas 
cerebrospinal fluid and vitreous humor (VH) levels were inthe 
range of the peripheral blood concentration. These latter values 
probably reflect more accurately perimortem concentrations be- 
cause these specimens are relatively protected and less sub- 
jected to drug degradation a d redistribution (43). Perimortem 
VH cocaine concentrations were significantly lower than peri- 
mortem femoral concentrations i  a administration study car- 
ried out with 9 swines (45). Bythe end of an 8-h postmortem 
interval, however, VII cocaine concentrations increased to reach 
the cocaine concentration measured in perimortem femoral 
blood. This administration study demonstrates that VH con- 
centrations change after death. It shows also that VH should not 
be considered as thespecimen ofchoice to evaluate peripheral 
blood concentration at the time of death. The skeletal muscle 
has also been investigated as an alternative to peripheral blood 
for intoxication diagnosis. Unfortunately, it has been shown 
that large site-to-site variability exists (46). Cocaine concen- 
tration of skeletal muscle was similar to cardiac blood, pericar- 
dial fluid, and liver values and about wice that of peripheral 
blood (Table V). It has been claimed that brain tissue is a useful 
specimen for the determination f cocaine and metabolites be- 
cause they are relatively stable in brain and not subjected to 
postmortem redistribution. Spiehler andReed (47) have shown 
that cocaine is evenly distributed throughout the brain and re- 
mains table for a long period in refrigerated tissue. More re- 
cently, Kalasinsky et al. (48) have also shown that 
concentrations of cocaine and of its major metabolites show 
little regional heterogeneity n postmortem brain of chronic 
users of cocaine. The mean blood concentrations were 4.6 mg/L 
of cocaine and 7.8 mg benzoylecgonine/L (this ca e: 5.0 and 
10.4 rag/L, respectively, Table V), the mean brain concentrations 
were 13.3 mg/kg of cocaine (this case: 21.2 mg/kg) and 2.9 
mg/kg of benzoylecgonine (this ca e: 3.8 mg/kg) (44). They 
also reported that in cocaine overdose cases, th  mean brain to 
blood ratio was 9.6 (range: 0.65-155) for cocaine and 0.36 
(range: 0.04-1.0) for benzoylecgonine. The same ratios calcu- 
lated for the present case are 4.2 and 0.36, respectively. Animal 
studies have demonstrated that cocaine readily crosses the 
blood-brain barrier and that brain concentrations are about 
four times those of plasma t peak plasma concentrations (49). 
All these data indicate an acute cocaine overdose. 
Buprenorphine. LC-MS only was sensitive nough to confirm 
the presumptive positive result of the buprenorphine radioim- 
munoassay. Buprenorphine, anopioid mixed agonist-antago- 
nist, is a potent analgesic widely used in the treatment ofopiate 
ab se. In Switzerland, methadone is preferred to buprenor- 
phine for long lasting substitution therapy. Buprenorphine 
(Subutex | is generally prescribed for sh rt-term substitution 
therapy to patients enrolled in a detoxification process (50). As 
far as we know, buprenorphine is not prescribed todiminish the 
craving for cocaine. A trace amount of 6-monoacetylmorphine 
could be detected in haironly. Morphine was not detected inbi- 
ological fluids suggesting that he buprenorphine substitution 
therapy was successful, at least as far as opiate abuse is con- 
cerned. 
Table VI. Body Fluid and Tissue Distribution of Minor Metabolites of Cocaine Determined by HILIC LC-MS 
Ecgonine m-Hydroxy- Anydroecgonine 
Specimen Cocaethylene Norcocaine Nor-Cocaelhylene Ethylester Benzoylecgonine Methylester 
Peripheral blood nd* 0.08 mg/L nd nd 0.089 mg/L 0.02 mg/L 
Brain cortex nd 0.76 mg/kg nd nd nd 0.20 mg/kg 
Liver nd 0.25 mg/kg nd traces 0.73 mg/kg 0.10 mg/kg 
Muscle nd 0.24 mg/kg nd nd nd 0.12 mg/kg 
Urine nd 0.96 mg/L nd traces 13.6 mg/L 0.65 mg/L 
Bile nd 0.99 mglL nd nd 1.2 mglL 0.I 8 mglL 
*nd, not detected. 
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According to Tracqui et al. (32), fatalities involving buprenor- 
phine alone seem very unusual. Therapeutic concentrations of 
buprenorphine are in the range 0.5-5.0 lag/L (51). Blood levels 
for 20 fatalities ranged from 1.1 to 29.0 lag buprenorphine/L and 
0.2 to 12.6 lag norbuprenorphine/L (32). The concentrations 
found in the present case (Table VII) are below or in the low 
therapeutic range. The unusually high norbuprenorphine to 
buprenorphine concentration ratio suggests that death oc- 
curred late in the elimination curve. 
Fluoxetine. Fluoxetine isan antidepressant often prescribed 
to addicts. Its clinical efficacy in ombination with buprenor- 
phine as a anti-craving medication has been shown to be less ef- 
ficient than tricyclics (desipramine) and amantadine (52). To 
cure depression of cocaine addicts, Swiss practitioners prefer to 
administrate s dative antidepressants (e.g., mirtazapine). Flu- 
oxetine, which is known to be a strong P-450 enzyme inhibitor 
should be administred with caution because of the high risk of 
pharmacokinetic interactions with other drugs metabolised 
through the P-450 pathways. For instance, norfluoxetine is 
known to inhibit the metabolism of both methadone and 
buprenorphine in vitro (53). Fluoxetine toxicity appears to be 
relatively benign (54). The concentrations determined in the 
blood from our case (Table VII) are within the therapeutic range 
(51). Symptoms of toxicity have been correlated with blood 
concentrations higher than ] mg/L. In the absence of other isk 
factors, the lowest concentration determined to have resulted in 
death was 0.63 mg/L (55). Nevertheless, fluoxetine intake may 
present a significant risk factor for patients with atherosclerotic 
cardiovascular disease. Cardiovascular toxic effects, such as 
ventricular torsade, conduction abnormality, and ventricular 
tachyarrhythmia, and seizures have been occasionally reported 
(56-58). These unwanted toxic effects again indicate that flu- 
oxetine must be prescribed to cocaine addicts with caution. On 
the other hand, no adverse physiological nteractions between 
the two drugs have been observed in cardiovascular tests of 
patients challenged with ascending doses of cocaine (20-40 
rag) and fluoxetine (10-40 rag) (59). 
Cannabinoids. Cannabinoids were measured in relatively 
high concentrations in blood, urine, and brain cortex (Table 
VII). The blood concentrations of THC and 11-OH-THC suggest 
that the victim was under the influence of cannabis at the time 
of death (60). Mathematical models have been proposed to eval- 
Table VII. Buprenorphine, Fluoxetine, and Cannabinoid 
Concentrations in Biological Samples 
Peripheral Blood Urine Brain Cortex 
Xenobiotic (pg/L) (pg/L) (pg/kg) 
Buprenorphine 0.1 16.3' n/m t 
Norbuprenorphine 0.6 24.3* n/m 
Fluoxetine 150 180 n/m 
Norfluoxetine 330 280 n/m 
THC 8.2 n/m 13.5 
11-OH-THC 2.1 n/m 11.5 
THCCOOH 18.6 696.4* 23.5 
* After hydrolysis. 
t n/m, not measured. 
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uate the time of administration, and in a roundabout way the 
time-period ofinfluence from THC and THCCOOH concentra- 
tions in blood. However, these models have been validated with 
living people only (61) and are therefore difficult o implement 
in death cases. 
The process of postmortem redistribution can affect he con- 
centration of all analytes in body fluids and tissues. Cell lysis 
causes changes in drug concentrations along gradients of dif- 
fusion (42,43). The extent of postmortem redistribution is par- 
ticulary significant for d ugs with high lipid solubility or large 
volume of distribution (e.g., cannabinoids). In addition, the ex- 
tent of postmortem degradation of cannabinoids i  not yet 
known (62). It is thought that brain concentrations are less in- 
fluenced by drugs released from fat compartments and that 
brain concentrations reflect direct influence of the drug on the 
behavior (43). Nevertheless, in that case, brain cannabinoids 
levels were in a similar range as those measured in the blood, 
suggesting that massive postmortem redistribution did not 
occur. It is also worth mentioning that in vitro experiments with 
the aim of studying the neuroactive and neurotoxic effects of 
THC are often carried out with very high concentrations of 
cannabinoids, typically 3-10laM THC (63). These values are at 
least two rders of magnitude higher than that which was found 
here (0.0431aM), suggesting that pharmacological studies w th
brain tissues must be carried out with lower, more realistic 
cannabinoid concentrations. 
Like cocaine, cannabinoids also affect he cardiovascular 
system. THC can induce tachycardia, orthostatic hypotension, 
and decreased platelet aggregation. Exposure to cannabinoids 
may also aggravate pre-existing cardiovascular illness (64). Al- 
though cannabis toxicity is considered tobe low, acute cardio- 
vascular fatalities following cannabis use have b en reported 
(65), suggesting that cannabinoids might have enhanced the 
toxic effects ofcocaine. Marijuana and cocaine have been shown 
to interact to increase heart rate above normal levels compared 
to the effects of each drug alone (66). 
Suicide or accidentaloverdose? A significant proportion of co- 
caine-related deaths are probably intentional but are not de- 
tected as such because no notes expressing intent are found at 
the scene of death (67). Compulsive self-administration of c - 
caine by injection may also result in accidental death. It has 
been suggested that a lethal overdosage is more likely to occur 
with injection than with other outes of administration (68). 
Conclusions 
Unlike other HPLC methods based on reversed-phase sepa- 
ration, Atlantis silica-packed HILIC columns allow the anal- 
ysis of basic molecules characterized by a broad r nge f polarity 
(e.g., cocaine and metabolites). Furthermore, acetonitrile con- 
stitutes a weak solvent and can be injected irectly into the 
LC-MS. The proportion of acetonitrite is kept high during the 
whole experiment improving the spraying conditions a d cou- 
pling with the MS. LC-MS presents he additional advantage of 
no AEME formation and no required erivatization step. 
The method was successfully applied to a death case after 
Journal of Analytical Toxicology, Vol. 28,September 2004 
multiple cocaine injections. Altogether, the toxicological re- 
suits indicate a lethal cocaine overdose. In addition, fluoxetine 
might have enhanced the toxic effects ofcocaine because of its 
weak pro-arrhythmogenic properties. Likewise, combination 
of cannabinoids and cocaine might have increased detrimental 
cardiovascular effects. 
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